MAPK14 and cancer: Integrating network pharmacology with molecular docking, our research elaborated that SC could prevent or reduce lung metastasis of malignant tumor to some extent by its active components through targeting RELA, JUN, MAPK1, MAPK14, STAT3, IL-4, ESR1, and TP53.